Linda Montgomery • June 28, 2023
Free Flights for Medical Appointments 

We recently met with a wonderful organization that supplies flights to those in need.  It is a non-profit organization that can get you to an HCMA Recognized Center of Excellence.  

The organization is called Angel Flights East. They are mainly in the North East but can fly up to 1,000 miles.  Should your trip be longer, they will work with their partners nationwide to get you to your destination. There is a quick and simple process for approval. They have been helping patients in need for thirty years.

Some of their pilots have flown commercial airplanes and have five times more flight time relative to what the FAA requires.  There are no TSA issues to deal with; they usually have clearance to land within a few miles of major hospitals.

They have added ‘ground service’ to get you from the plane to your destination.  Should you need a car service, they can help. 

This group is dedicated to getting you to the care you need.  You deserve the best care.  To contact Angel Flights East,  call 973-983-7429 or go to their website at  https://angelflighteast.org/

HCMA Blog

Pro Publica Releases Results of FDA Investigation

By Erica Friedman • June 26, 2025
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of generic drugs coming into the United States from overseas. Among the many voices that spoke up for American patients was HCMA Founder and CEO, Lisa Salberg who has felt the effects of low-quality drugs personally. Salberg believes that fixing this problem is something we can do, even in this time, when even health care is highly politicized. Read the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers in Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs .
A light blue and dark blue paintbrush stroke intersect to make a stylized

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran) for Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
More Posts